Amgen readies PhIII trial for first Opdivo biosimilar, with launch unlikely before 2028
The race to end Bristol Myers Squibb’s exclusivity on its megablockbuster cancer drug Opdivo (nivolumab) is beginning in earnest, with Amgen looking to kick off …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
